HB0025

· Huabo Biopharm Co., Ltd.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for HB0025, covering 2024-01-24 to 2026-02-03. Get the full timeline:

Most recent: Clinical Trial Update: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer [Phase 3]

See pricing